Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available...
Guardado en:
Autores principales: | Nina A. Petunina, Milena Е. Telnova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017) -
The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016) -
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
por: Elena Nikolaevna Trunina, et al.
Publicado: (2011) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020)